|
|
Article: Aureon Discloses $15M Round To Develop Cancer Diagnostics.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Aureon Biosciences Corp. CEO Jon Edelson is banking on his company finding an integrated clinical view of disease through diagnostic tests for cancer - tests that may be able to tell a patient if he or she is going to die and when, or what the most beneficial course of treatment might be.
The Yonkers, N.Y.-based company also raised $15 million late last year, which it announced this week, with investments from The Sprout Group, of Menlo Park, Calif., and New York, and Atlas Venture, of Boston.
"There are two ways of looking at it," Edelson told BioWorld Today in explaining, as a co-founder, the reasons for starting the company. ...